Nexstim Targets US Stroke Rehab Market With MRI-Guided Transcranial Magnetic Stimulation
This article was originally published in The Gray Sheet
Executive Summary
Noninvasive Navigated Brain Therapy system is undergoing a pivotal study in the US to improve brain function following a stroke.
You may also be interested in...
Nexstim Looks To Break Into US TMS Market With Depression Indication
The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.